Literature DB >> 21456047

Copy number profiling in von Hippel-Lindau disease renal cell carcinoma.

Salwati Shuib1, Wenbin Wei, Hariom Sur, Mark R Morris, Dominic McMullan, Eleanor Rattenberry, Esther Meyer, Patrick H Maxwell, Takeshi Kishida, Masahiro Yao, Farida Latif, Eamonn R Maher.   

Abstract

Germline mutations in the VHL tumor suppressor gene cause von Hippel-Lindau (VHL) disease and somatic VHL mutations occur in the majority of clear cell renal cell carcinoma (cRCC). To compare copy number abnormalities (CNAs) between cRCC from VHL patients and sporadic cRCC cases without detectable somatic VHL mutations, we analyzed 34 cRCC with Affymetrix 250K arrays. To increase the power of the study, we then combined our results with those of a previously published study and compared CNAs in VHL and non-VHL related cRCC using the genomic identification of significant targets in cancer (GISTIC) program. In VHL, cRCC GISTIC analysis identified four statistically significant regions of copy number gain and four statistically significant regions of deletion that occurred in >10% of tumors analyzed. Sporadic cRCC without detectable VHL mutations had, on average, more copy number abnormalities than VHL cRCC though the most common regions of loss/gain (e.g., 3p and 14q loss and 5q gain) were present in both tumor sets. However, CNAs on chromosome arms 7p (gain) and 8p (loss) were only detected in VHL RCC. Although individual copy number abnormality peaks contained clear candidate cancer genes in some cases (e.g., the 3p loss peak in VHL cRCC contained only six genes including VHL), most peaks contained many genes. To date, only a minority of the candidate genes included in these peaks have been analyzed for mutation or epigenetic inactivation in cRCC but TNFRSF10C and DUSP4 map to the 8p region deleted in VHL cRCC and TP53 and HIF2A (EPAS1) mapped to CNA loss and gain peaks (chromosomes 17 and 2, respectively) detected in sporadic VHL wild-type cRCC.

Entities:  

Mesh:

Year:  2011        PMID: 21456047     DOI: 10.1002/gcc.20865

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Association of Abl interactor 2, ABI2, with platelet/lymphocyte ratio in patients with renal cell carcinoma: A pilot study.

Authors:  Sercan Ergun; Sezgin Gunes; Recep Buyukalpelli; Oguz Aydin
Journal:  Int J Exp Pathol       Date:  2020-06-04       Impact factor: 1.925

2.  Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.

Authors:  Shunsaku Takayanagi; Akitake Mukasa; Shota Tanaka; Masashi Nomura; Mayu Omata; Shunsuke Yanagisawa; Shogo Yamamoto; Koichi Ichimura; Hirofumi Nakatomi; Keisuke Ueki; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

3.  Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.

Authors:  A Murakami; L Wang; S Kalhorn; P Schraml; W K Rathmell; A C Tan; R Nemenoff; K Stenmark; B-H Jiang; M E Reyland; L Heasley; C-J Hu
Journal:  Oncogenesis       Date:  2017-01-16       Impact factor: 7.485

4.  Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.

Authors:  Katarzyna Kluzek; Malgorzata I Srebniak; Weronika Majer; Agnieszka Ida; Tomasz Milecki; Kinga Huminska; Robert M van der Helm; Adrian Silesian; Tomasz M Wrzesinski; Jacek Wojciechowicz; Berna H Beverloo; Zbigniew Kwias; Hans A R Bluyssen; Joanna Wesoly
Journal:  Oncotarget       Date:  2017-04-25

5.  Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.

Authors:  Charles-Henry Gattolliat; Sophie Couvé; Guillaume Meurice; Cédric Oréar; Nathalie Droin; Mathieu Chiquet; Sophie Ferlicot; Virginie Verkarre; Viorel Vasiliu; Vincent Molinié; Arnaud Méjean; Philippe Dessen; Sophie Giraud; Brigitte Bressac-De-Paillerets; Betty Gardie; Bin Tean Teh; Stéphane Richard; Sophie Gad
Journal:  Int J Oncol       Date:  2018-07-19       Impact factor: 5.650

6.  PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.

Authors:  Xiaorong Gu; Francis Enane; Rita Tohme; Caroline Schuerger; Tomas Radivoyevitch; Yvonne Parker; Eric Zuberi; Bartlomiej Przychodzen; Babal Kant Jha; Daniel Lindner; Brian Rini; Yogen Saunthararajah
Journal:  Cell Rep       Date:  2021-09-21       Impact factor: 9.423

7.  Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Authors:  L E Moore; E Jaeger; M L Nickerson; P Brennan; S De Vries; R Roy; J Toro; H Li; S Karami; P Lenz; D Zaridze; V Janout; V Bencko; M Navratilova; N Szeszenia-Dabrowska; D Mates; W M Linehan; M Merino; J Simko; R Pfeiffer; P Boffetta; S Hewitt; N Rothman; W-H Chow; F M Waldman
Journal:  Oncogenesis       Date:  2012-06-25       Impact factor: 7.485

8.  Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.

Authors:  Christopher J Ricketts; Mark R Morris; Dean Gentle; Salwati Shuib; Michael Brown; Noel Clarke; Wenbin Wei; Paul Nathan; Farida Latif; Eamonn R Maher
Journal:  Clin Epigenetics       Date:  2013-09-13       Impact factor: 6.551

9.  Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma.

Authors:  Mika Takahashi; Yoshiyuki Tsukamoto; Tomoki Kai; Akinori Tokunaga; Chisato Nakada; Naoki Hijiya; Tomohisa Uchida; Tsutomu Daa; Takeo Nomura; Fuminori Sato; Hiromitsu Mimata; Keiko Matsuura; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2016-03-04       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.